# A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

> **NCT02821754** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Biliary Tract Neoplasms
- Liver Cancer
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Bile Duct Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **PROCEDURE:** Trans-arterial Catheter Chemoembolization (TACE)
- **PROCEDURE:** Radiofrequency Ablation (RFA)
- **PROCEDURE:** Cryoablation

## Key facts

- **NCT ID:** NCT02821754
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-05
- **Primary completion:** 2021-02-17
- **Final completion:** 2022-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821754, "A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02821754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*